A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients with Mild Alzheimer’s Disease.

Alzheimer's disease - and now?

The IONIS-MAPTRX-CS1 study will allow physicians to evaluate the safety and efficacy of the investigational drug and compare it to a placebo that looks like the investigational drug but does not contain any active ingredients.

The investigational drug is in clinical research and is not approved for commercial use by any authority.

Further information on this clinical research study is available here:

Principle Investigator: Prof. Dr. Anja Schneider
Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)
Venusberg-Campus 1, Gebäude 99, D-53127 Bonn
+49 228 43302-849


Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Inform yourself on our website cookie-free. However, we would be pleased if you would allow us to use statistical cookies. Your browser settings regarding cookies are currently as follows:
More information can be found in our Privacy policy.